文献速递乳腺癌放疗放疗物理与技术

与乳腺放射性肉瘤风险相关的治疗相关因素

Treatment related factors associated with the risk of breast radio-induced-sarcoma.
PubMed 文献 · Radiother Oncol · 2022-04-09

该研究利用患者代表性体素化拟人模体重建125例原发性乳腺癌后发生放射性肉瘤(RIS)患者的放疗野,计算RIS发生部位的剂量分布。结果显示RIS发生区域的平均剂量为47.8±11.6 Gy,RIS发生部位的中位剂量范围为11 Gy至58.8 Gy,从放疗到RIS发生的中位时间为8年(范围2-32年)。分析显示患者放疗时年龄对RIS发生时间有显著影响,而化疗和内分泌治疗与RIS诊断时间无显著差异。

要点

  • 125例乳腺癌放疗后发生放射性肉瘤的患者中,RIS发生区域的平均剂量为47.8±11.6 Gy。
  • RIS发生部位的中位剂量范围为11 Gy至58.8 Gy,从放疗到RIS发生的中位时间为8年(范围2-32年)。
  • 患者放疗时年龄对RIS发生时间有显著影响,化疗和内分泌治疗与RIS诊断时间无显著差异。

核心结论

  • 本研究表明,发生放射性肉瘤的组织所接受的剂量接近47 Gy。
  • 这些结果鼓励使用增加低剂量受照体积的新放疗技术,而无需担心未来10年内放射性肉瘤风险过度增加。

研究设计与样本

  • 研究使用患者代表性体素化拟人模体,为125例原发性乳腺癌后诊断为放射性肉瘤的患者重建个体化放疗野。
  • 对每例患者确定放射性肉瘤发生部位的位置并作为轮廓转移到模体上,使用治疗计划系统(TPS)计算模体上放射性肉瘤部位的剂量分布。

主要发现

  • 放射性肉瘤 subsequently 发生区域接受的平均剂量(Dmean)为47.8±11.6 Gy。
  • 放射性肉瘤 later 发生的区域的中位剂量范围为11 Gy至58.8 Gy。
  • 从放疗到放射性肉瘤发生的中位时间为8年(范围2-32年)。
  • 对放射性肉瘤发生时间预测因素的分析突出显示患者放疗时年龄有显著影响。
  • 多因素分析中,针对原发性乳腺癌的化疗和内分泌治疗与放射性肉瘤诊断时间无显著差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: The Radiation Induced Sarcoma (RIS) is a rare but serious adverse event following radiotherapy (RT). Current RT techniques are more precise, but irradiate a larger volume at a low dose. This study aimed to describe radiation characteristics in a large series of patients suffering from RIS. MATERIALS AND METHODS: Patient-representative voxel-based anthropomorphic phantoms were used to reconstruct patient-specific RT fields for 125 patients diagnosed with RIS after primary breast cancer. For each patient, the location of the RIS onset site was determined and transferred onto the phantom as a contour. Using a treatment planning system (TPS), the dose distribution on the RIS in the phantom was calculated. RESULTS: The mean dose (Dmean) received in the area where RIS subsequently developed was 47.8 ± 11.6 Gy. The median dose in the zones where RIS later developed ranged from 11 Gy to 58.8 Gy. The median time from RT to RIS development was 8 years (range 2-32 years). Analysis for predictors of time to radiation-induced sarcoma development highlighted a significant impact of age of patient during the RT whereas in multivariable analysis chemotherapy and hormonotherapy for primary breast cancer were not associated with a significant difference in time to diagnosis of RIS. CONCLUSIONS: This study highlights that the dose received by the tissue in which the RIS developed was almost 47 Gy. These results are encouraging for the use of new RT techniques increasing volumes receiving low doses, without fear of an excess of RIS over the next 10 years.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Mirjolet C, Diallo I, Bertaut A, et al. Treatment related factors associated with the risk of breast radio-induced-sarcoma. Radiother Oncol. 2022. PMID: 35405175. doi:10.1016/j.radonc.2022.04.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。